207 related articles for article (PubMed ID: 29593202)
1. A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.
Tsuboi M; Kondo K; Takizawa H; Kawakita N; Sawada T; Toba H; Kawakami Y; Yoshida M; Ishikura H; Kimura S; Tangoku A
J Med Invest; 2018; 65(1.2):90-95. PubMed ID: 29593202
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study.
Yano T; Yamazaki K; Maruyama R; Tokunaga S; Shoji F; Higashi H; Takeo S; Ichinose Y; Maehara Y;
Lung Cancer; 2010 Feb; 67(2):184-7. PubMed ID: 19409643
[TBL] [Abstract][Full Text] [Related]
4. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301.
Okumura N; Soh J; Suzuki H; Nakata M; Fujiwara T; Nakamura H; Sonobe M; Fujinaga T; Kataoka K; Gemba K; Kataoka M; Hotta K; Yoshioka H; Matsuo K; Sakamoto J; Date H; Toyooka S
BMC Cancer; 2021 May; 21(1):506. PubMed ID: 33957881
[TBL] [Abstract][Full Text] [Related]
6. Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.
Iwamoto Y; Mitsudomi T; Sakai K; Yamanaka T; Yoshioka H; Takahama M; Yoshimura M; Yoshino I; Takeda M; Sugawara S; Kawaguchi T; Takahashi T; Ohta M; Ichinose Y; Atagi S; Okada M; Saka H; Nakagawa K; Nakanishi Y; Nishio K
Clin Cancer Res; 2015 Dec; 21(23):5245-52. PubMed ID: 26253869
[TBL] [Abstract][Full Text] [Related]
7. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
[TBL] [Abstract][Full Text] [Related]
8. Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701.
Soh J; Okumura N; Nakata M; Nakamura H; Fukuda M; Kataoka M; Kajiwara S; Sano Y; Aoe M; Kataoka K; Hotta K; Matsuo K; Toyooka S; Date H
Jpn J Clin Oncol; 2016 Aug; 46(8):741-7. PubMed ID: 27207886
[TBL] [Abstract][Full Text] [Related]
9. Feasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected non-small cell lung cancer.
Komazaki Y; Sakashita H; Furuiye M; Fujie T; Tamaoka M; Sumi Y; Miyazaki Y; Kojima K; Jin Y; Inase N
Chemotherapy; 2013; 59(1):35-41. PubMed ID: 23816760
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer.
Tanaka H; Tabe C; Okumura F; Shiratori T; Ishioka Y; Itoga M; Taima K; Morimoto T; Kimura D; Tsushima T; Tasaka S
Thorac Cancer; 2020 Jun; 11(6):1633-1638. PubMed ID: 32351044
[TBL] [Abstract][Full Text] [Related]
11. UFT and S-1 for treatment of primary lung cancer.
Tanaka F; Wada H; Fukushima M
Gen Thorac Cardiovasc Surg; 2010 Jan; 58(1):3-13. PubMed ID: 20058135
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.
Okumura N; Sonobe M; Okabe K; Nakamura H; Kataoka M; Yamashita M; Nakata M; Kataoka K; Yamashita Y; Soh J; Yoshioka H; Hotta K; Matsuo K; Sakamoto J; Toyooka S; Date H
Int J Clin Oncol; 2017 Apr; 22(2):274-282. PubMed ID: 27921177
[TBL] [Abstract][Full Text] [Related]
13. Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
Hata Y; Kiribayashi T; Kishi K; Nagashima M; Nakayama T; Ikeda S; Kadokura M; Ozeki Y; Otsuka H; Murakami Y; Takagi K; Iyoda A
BMC Cancer; 2017 Aug; 17(1):581. PubMed ID: 28851314
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of postoperative adjuvant chemotherapy using carboplatin plus S-1 in completely resected non-small cell lung cancer patients.
Inoue M; Kusumoto H; Shiono H; Shintani Y; Ose N; Sakamaki Y; Okami J; Higashiyama M; Takeuchi Y
J Chemother; 2019 Oct; 31(6):343-348. PubMed ID: 31409216
[TBL] [Abstract][Full Text] [Related]
17. Feasibility Trial of Oral UFT after Platinum-based Adjuvant Chemotherapy in Patients with Resected Non-small Cell Lung Cancer.
Sawada S; Sugimoto R; Ueno T; Yamashita M
Acta Med Okayama; 2017 Dec; 71(6):513-518. PubMed ID: 29276224
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral gene expression of 5-fluorouracil pharmacokinetics-related enzymes in stage I and II non-small cell lung cancer patients treated with uracil-tegafur after surgery: a prospective multi-institutional study in Japan.
Eguchi K; Oyama T; Tajima A; Abiko T; Sawafuji M; Horio H; Hashizume T; Matsutani N; Kato R; Nakayama M; Kawamura M; Kobayashi K
Lung Cancer; 2015 Jan; 87(1):53-8. PubMed ID: 25468199
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
Tsuchiya T; Matsumoto K; Miyazaki T; Doi R; Tokunaga S; Yamaguchi H; Tomoshige K; Watanabe H; Nagayasu T; Sugio K
BMC Cancer; 2021 Mar; 21(1):249. PubMed ID: 33685421
[TBL] [Abstract][Full Text] [Related]
20. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
